Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Minjing Li

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

Bioscience Reports

English

Related publications

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

English

Toward Precision Medicine With Next-Generation EGFR Inhibitors in Non-Small-Cell Lung Cancer

Pharmacogenomics and Personalized Medicine

Molecular Medicine

Pharmacology

2014

English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research

Oncology

2017

English

Molecular Imaging for Detection of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Clinical and Translational Imaging

English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice

Oncology

2019

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

English

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Minjing Li

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

Related publications

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Toward Precision Medicine With Next-Generation EGFR Inhibitors in Non-Small-Cell Lung Cancer

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Molecular Imaging for Detection of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M